Researchers from Stony Brook University Renaissance School of Medicine recently disclosed the design and development of a novel, multitargeted miRNA approach based on a gemcitabine-modified microRNA (miR)-129 mimic (Gem-miR-129) to overcome resistance to EGFR inhibitors.
Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer.
Urogen Pharma Ltd. has obtained IND approval from the FDA for UGN-501, a next-generation investigational oncolytic virus. A phase I study evaluating intravesical administration of UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC) is expected to begin in the fourth quarter.
While the emergence of immune checkpoint inhibitor (ICI) therapy in recent years has significantly improved cancer outcomes, some patients have been unable to experience the full therapeutic benefits of ICIs due to significant gastrointestinal inflammation linked to treatment. Seres Therapeutics Inc. is looking to change that with its live biotherapeutic candidate, SER-155, offering impressive findings from phase I data in ICI-related enterocolitis, or irEC.
A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC).
KU Leuven and Universität Zürich have discovered new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors potentially useful for the treatment of cancer and metabolic diseases.
Pikavation Therapeutics Inc. has patented new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.
To compare the expanding range of CBP/p300-directed cancer therapeutics, Massachusetts General Hospital scientists and collaborators analyzed inhibitors and degraders across a large panel of cancer cell lines.
Researchers from Hainan Medical University and collaborators have demonstrated that PGE2-EP2/EP4-G α s-PKA signaling drove the expansion of immunosuppressive VSIG4-high macrophages and promoted immunotherapy resistance in colorectal cancer (CRC).
RSS
